Pulmonary Fibrosis

Strategies that combine ferroptosis inhibition with established antifibrotics could ultimately move treatment from slowing progression to truly reversing fibrosis, new research suggests.

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery.

Telomere length can be used in the diagnosis of interstitial lung diseases like idiopathic pulmonary fibrosis, but it likely also has therapeutic implications, according to a new report.

Patients with idiopathic pulmonary fibrosis are at a higher risk of certain cardiovascular diseases.

From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

Factors such as age, smoking status, and body mass index can help clinicians predict a patient’s risk of 30-day mortality.

With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis.

The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.

While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment helped slow disease progression and gave them hope.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.

Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new drug trials; the impact of diabetes on pulmonary health; and the growing body of research on macrophages and pulmonary fibrosis.

Patients with interstitial lung disease (ILD) experience significantly higher rates of fatigue and excessive daytime sleepiness than healthy individuals.